UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease

Blennow, Kaj; Stomrud, Erik; Zetterberg, Henrik; Borlinghaus, Niels; Corradini, Veronika; Manuilova, Ekaterina; Muller-Hubner, Laura; ... Hansson, Oskar; + view all (2022) Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease. Clinical Chemistry and Laboratory Medicine , 61 (2) pp. 234-244. 10.1515/cclm-2022-0516. Green open access

[thumbnail of 10.1515_cclm-2022-0516.pdf- Published version.pdf]
Preview
Text
10.1515_cclm-2022-0516.pdf- Published version.pdf

Download (841kB) | Preview

Abstract

OBJECTIVES: Timely diagnosis of Alzheimer's disease (AD) is critical for appropriate treatment/patient management. Cerebrospinal fluid (CSF) biomarker analysis is often used to aid diagnosis. We assessed analytical performance of second-generation (Gen II) Elecsys® CSF immunoassays (Roche Diagnostics International Ltd), and adjusted existing cut-offs, to evaluate their potential utility in clinical routine. METHODS: Analytical performance was assessed using CSF samples measured with Elecsys CSF Gen II immunoassays on cobas e analyzers. Aβ42 Gen I/Gen II immunoassay method comparisons were performed (Passing-Bablok regression). Cut-off values were adjusted using estimated bias in biomarker levels between BioFINDER protocol aliquots/Gen I immunoassays and Gen II protocol aliquots/immunoassays. Distribution of Gen II immunoassay values was evaluated in AD, mild cognitive impairment (MCI), and cognitively normal cohorts; percentage observations outside the measuring range were derived. RESULTS: The Gen II immunoassays demonstrated good analytical performance, including repeatability, intermediate precision, lot-to-lot agreement (Pearson's r: ≥0.999), and platform agreement (Pearson's r: ≥0.995). Aβ42 Gen I/Gen II immunoassay measurements were strongly correlated (Pearson's r: 0.985-0.999). Aβ42 Gen II immunoassay cut-offs were adjusted to 1,030 and 800 ng/L, and pTau181/Aβ42 ratio cut-offs to 0.023 and 0.029, for Gen II and I protocols, respectively. No observations were below the lower limit of the measuring range; above the upper limit, there were none from the AD cohort, and 2.6 and 6.8% from the MCI and cognitively normal cohorts, respectively. CONCLUSIONS: Our findings suggest that the Gen II immunoassays have potential utility in clinical routine to aid diagnosis of AD.

Type: Article
Title: Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease
Location: Germany
Open access status: An open access version is available from UCL Discovery
DOI: 10.1515/cclm-2022-0516
Publisher version: https://doi.org/10.1515/cclm-2022-0516
Language: English
Additional information: Copyright © 2022 the author(s), published by De Gruyter, Berlin/Boston. This work is licensed under the Creative Commons Attribution 4.0 International License.
Keywords: Alzheimer’s disease; beta-amyloid (1–42); biomarkers; cerebrospinal fluid; phosphorylated tau 181P; total tau
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10159380
Downloads since deposit
20Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item